PVR and head and neck squamous cell carcinoma: In head and neck squamous cell carcinoma (HNSCC), CD155 expression on MDSCs promoted MDSCs-mediated T-cell suppression, and in vitro blocking the TIGIT/CD155 pathway with anti-TIGIT antibodies substantially inhibited MDSCs immunosuppressive capacity and enhanced the antitumor immune response [53].